Pharmabiz21h
Biocon introduces glucagon-like peptide-1, Liraglutide in United Kingdom
Liraglutide in United Kingdom: Our Bureau, Bengaluru Friday, February 28, 2025, 15:30 Hrs [IST] Biocon Limited, an innovation-led global ...
Medscape2d
The Glucagonostatic and Insulinotropic Effects of Glucagon-like Peptide 1 Contribute Equally to its Glucose-lowering Action
Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...
2minutemedicine.com4d
Glucagon-like peptide-1 receptor agonists associated with lower depression risk in older adults with diabetes
In this target trial emulation, glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a lower risk of ...
Modern Healthcare1d
GLP-1 compounding pharmacies sue FDA over shortage decision
Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...
Medscape1d
GLP-1 Exposure Before and During Pregnancy Linked to Contradictory Outcomes
While one study found lower rates of preterm birth alongside higher rates of hypertensive disorders, another found fewer ...
Study finds GLP-1 receptor agonists target fat over muscle for weight loss
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class ...
Depression risk lower with GLP-1 receptor agonists versus DPP-4 inhibitors in seniors, study reveals
For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with ...
FoodNavigator4d
Is this GLP-1.2? New generation of weight-loss drugs moving in
CagriSema from Novo Nordisk activates both GLP-1 and amylin receptors. It is currently the subject of several clinical trials ...
Science Daily4d
Genetic evidence that diabetes drug GLP-1 receptor agonists achieve weight loss primarily by reducing fat mass more than muscle
Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...
TCTMD2d
GLP-1 Drugs in Diabetes Don’t Raise Suicidality Risk, New Data Confirm
A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.
BMJ2d
GLP-1 receptor agonists and suicidality
Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...